RelA, p50 and Inhibitor of kappa B alpha are Elevated in Human Metastatic Melanoma Cells and Respond Aberrantly to Ultraviolet Light B

Metastatic melanomas are typically resistant to radiation and chemotherapy. The underlying basis for this phenomenon may result in part from defects in apoptotic pathways. Nuclear factor kappa B (NFκB) has been shown to control apoptosis in many cell types and normally functions as an immediate stre...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pigment cell research 2001-12, Vol.14 (6), p.456-465
Hauptverfasser:	McNulty, Susan E., Tohidian, Niloufar B., Meyskens Jr, Frank L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Active Transport, Cell Nucleus - drug effects Active Transport, Cell Nucleus - physiology Active Transport, Cell Nucleus - radiation effects Antisense Binding Sites - drug effects Binding Sites - physiology Cell Nucleus - drug effects Cell Nucleus - metabolism Cell Survival - drug effects Cell Survival - physiology Cytoplasm - metabolism Cytoplasm - radiation effects DNA-Binding Proteins - genetics DNA-Binding Proteins - metabolism DNA-Binding Proteins - radiation effects Humans I-kappa B Proteins Infant, Newborn Male Melanocyte Melanocytes - drug effects Melanocytes - metabolism Melanocytes - radiation effects Melanoma Melanoma - drug therapy Melanoma - metabolism Melanoma - radiotherapy Neoplasm Metastasis - drug therapy Neoplasm Metastasis - physiopathology Neoplasm Metastasis - radiotherapy NF-kappa B - genetics NF-kappa B - metabolism NF-kappa B - radiation effects NF-kappa B p50 Subunit NF-KappaB Inhibitor alpha NFκB RNA, Messenger - metabolism RNA, Messenger - radiation effects TNF Transcription Factor RelA Tumor Cells, Cultured - drug effects Tumor Cells, Cultured - metabolism Tumor Cells, Cultured - radiation effects Tumor Necrosis Factor-alpha - pharmacology Ultraviolet Rays Up-Regulation - genetics UVB
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!